Rob van der Kant
Overview
Explore the profile of Rob van der Kant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Delgado J, Reche R, Cianferoni D, Orlando G, van der Kant R, Rousseau F, et al.
Bioinformatics
. 2025 Feb;
41(2).
PMID: 39913370
Motivation: The FoldX force field was originally validated with a database of 1000 mutants at a time when there were few high-resolution structures. Here, we have manually curated a database...
2.
Holtz A, Van Weyenbergh J, Hong S, Cuypers L, OToole A, Dudas G, et al.
BMC Infect Dis
. 2024 Oct;
24(1):1139.
PMID: 39390446
We investigate the emergence, mutation profile, and dissemination of SARS-CoV-2 lineage B.1.214.2, first identified in Belgium in January 2021. This variant, featuring a 3-amino acid insertion in the spike protein...
3.
Michiels E, Roose K, Gallardo R, Khodaparast L, Khodaparast L, van der Kant R, et al.
Nat Commun
. 2023 Jun;
14(1):3492.
PMID: 37311856
No abstract available.
4.
Naus E, Derweduwe M, Lampi Y, Claeys A, Pauwels J, Langenberg T, et al.
Cells
. 2023 Mar;
12(6).
PMID: 36980299
In malignant cancer, excessive amounts of mutant p53 often lead to its aggregation, a feature that was recently identified as druggable. Here, we describe that induction of a heat shock-related...
5.
Janssen K, Claes F, Van de Velde D, Wehbi V, Houben B, Lampi Y, et al.
Proc Natl Acad Sci U S A
. 2023 Feb;
120(9):e2214921120.
PMID: 36812200
Mutant KRAS is a major driver of oncogenesis in a multitude of cancers but remains a challenging target for classical small molecule drugs, motivating the exploration of alternative approaches. Here,...
6.
van der Kant R, Louros N, Schymkowitz J, Rousseau F
Structure
. 2022 May;
30(8):1178-1189.e3.
PMID: 35609599
The increasing number of amyloid structures offers an opportunity to investigate the general principles determining amyloid stability and polymorphism. We find that amyloid stability is dominated by ∼30% of residues...
7.
Louros N, van der Kant R, Schymkowitz J, Rousseau F
Bioinformatics
. 2022 Feb;
38(9):2636-2638.
PMID: 35199146
Summary: Amyloid polymorphism is emerging as a key property that is differentially linked to various conformational diseases, including major neurodegenerative disorders, but also as a feature that potentially relates to...
8.
Michiels E, Roose K, Gallardo R, Khodaparast L, Khodaparast L, van der Kant R, et al.
Nat Commun
. 2020 Jun;
11(1):2832.
PMID: 32504029
Human amyloids have been shown to interact with viruses and interfere with viral replication. Based on this observation, we employed a synthetic biology approach in which we engineered virus-specific amyloids...
9.
Claes F, Rudyak S, Laird A, Louros N, Beerten J, Debulpaep M, et al.
Protein Eng Des Sel
. 2020 May;
32(10):443-457.
PMID: 32399571
The accumulation of toxic protein aggregates is thought to play a key role in a range of degenerative pathologies, but it remains unclear why aggregation of polypeptides into non-native assemblies...
10.
Van Nieuwenhove E, Barber J, Neumann J, Smeets E, Willemsen M, Pasciuto E, et al.
J Allergy Clin Immunol
. 2020 Apr;
146(5):1180-1193.
PMID: 32325141
Background: The molecular cause of severe congenital neutropenia (SCN) is unknown in 30% to 50% of patients. SEC61A1 encodes the α-subunit of the Sec61 complex, which governs endoplasmic reticulum protein...